{"disease":{"id":"treatment-failure","name":"treatment failure"},"drugs":{"marketed":[{"drug_id":"somatropin-adult-cohort","indication_name":"Treatment of short bowel syndrome and failure to thrive in adults.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"somatropin - adult cohort","generic_name":"somatropin-adult-cohort","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Growth Hormone Receptor","drug_class":"Growth Hormone","quality_score":10,"revenue":"446","mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pyrazinamide","indication_name":"Treatment after failure with other primary drugs","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pyrazinamide","generic_name":"PYRAZINAMIDE","company_name":"Dava Pharms Inc","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"Antimycobacterial [EPC]","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":12,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06617403","title":"Pre-operative Characteristics for Prediction of Supraglottic Airway Failure Using Machine Learning (ERICA)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":44000,"lead_sponsor_name":"University Hospital Ulm","has_results":false},{"nct_id":"NCT06371677","title":"Polish Nationwide Register of Hospitalized Patients in Cardiac Intensive Care Units","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Medical University of Warsaw","has_results":false},{"nct_id":"NCT03120065","title":"Virologic Treatment Failure and Drug Resistance in HIV-infected Kenyan Children (RESPECT)","phase":"NA","overall_status":"COMPLETED","enrollment_count":499,"lead_sponsor_name":"Rachel Vreeman, MD, MS","has_results":false},{"nct_id":"NCT05499403","title":"Incidence of the Treatment faIlure in Osteoporosis","phase":"","overall_status":"COMPLETED","enrollment_count":415,"lead_sponsor_name":"Centre Hospitalier Universitaire Vaudois","has_results":false},{"nct_id":"NCT04042662","title":"Predictors and Outcomes of Meropenem Treatment Failure Among Patients With Septic Shock in Intensive Care Unit","phase":"","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"Universiti Sains Malaysia","has_results":false},{"nct_id":"NCT03369093","title":"RCT of Efficacy of Amoxicillin Over Ampicillin on Severe Pneumonia","phase":"NA","overall_status":"COMPLETED","enrollment_count":308,"lead_sponsor_name":"International Centre for Diarrhoeal Disease Research, Bangladesh","has_results":false},{"nct_id":"NCT05074589","title":"Irinotecan Liposome in Combination With 5-FU/LV Versus 5-FU/LV in Second-line Therapy for Gemcitabine-Refractory Pancreatic Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":298,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT04580589","title":"DOAC ADRs Retrospective Study on Genetic Variations","phase":"","overall_status":"COMPLETED","enrollment_count":210,"lead_sponsor_name":"Cipherome, Inc.","has_results":false},{"nct_id":"NCT06146439","title":"The Factors Causing Treatment Failure in Children Receiving Oxygen Therapy With High-flow Nasal Cannula","phase":"","overall_status":"COMPLETED","enrollment_count":201,"lead_sponsor_name":"Dr. Behcet Uz Children's Hospital","has_results":false},{"nct_id":"NCT06892431","title":"JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":150,"lead_sponsor_name":"Shanghai JMT-Bio Inc.","has_results":false},{"nct_id":"NCT06717243","title":"Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)","phase":"","overall_status":"RECRUITING","enrollment_count":111,"lead_sponsor_name":"Oncology Center of Biochemical Education And Research","has_results":false},{"nct_id":"NCT07505511","title":"Visualization of the Effects of Guideline-directed Medical Therapy (GDMT) on Improving Adherence and Quality of Life in Heart Failure With Reduced Ejection Fraction (HFrEF)","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"University of Giessen","has_results":false},{"nct_id":"NCT05483348","title":"Clinical Predictive Factors of Success of Hysteroscopic Endometrial Ablation/Resection","phase":"","overall_status":"COMPLETED","enrollment_count":95,"lead_sponsor_name":"Naser Al-Husban","has_results":false},{"nct_id":"NCT07491796","title":"Comparison of One-Step and Two-Step Light Curing of Bonding Agents and Composite in Orthodontics","phase":"NA","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"Shaheed Zulfiqar Ali Bhutto Medical University","has_results":false},{"nct_id":"NCT07141459","title":"Efficacy of 810 nm Diode Laser Disinfection on Inflammatory Cytokines and Postoperative Pain After Endodontic Retreatment","phase":"NA","overall_status":"RECRUITING","enrollment_count":52,"lead_sponsor_name":"Al-Azhar University","has_results":false},{"nct_id":"NCT07101744","title":"Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":41,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06934811","title":"Ciprofol's Impact on Oxygenator Function in Extracorporeal Membrane Oxygenation (ECMO) Patients","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"First Affiliated Hospital of Wannan Medical College","has_results":false},{"nct_id":"NCT05283252","title":"The 3-Dimensional Printed Guide in Endodontic Microsurgery","phase":"NA","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"Damascus University","has_results":false},{"nct_id":"NCT07514429","title":"Regorafenib After Failure of Lenvatinib in Patients With Unresectable HCC: The RELEVANT-HCC Trial","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":24,"lead_sponsor_name":"Ju Hyun Shim","has_results":false},{"nct_id":"NCT07184151","title":"Evaluation of Guided Endodontic Microsurgery and Two Different Retrograde Filling Materials","phase":"NA","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Suez Canal University","has_results":false},{"nct_id":"NCT07514455","title":"Regorafenib After Treatment Failure of First Line Immune Checkpoint Inhibitor Treatment in Advanced Hepatocellular Carcinoma Patients","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Ju Hyun Shim","has_results":false}],"total":21},"guidelines":[],"source":"Drug Landscape verified database"}